Abatacept
The risk or severity of adverse effects can be increased when Abatacept is combined with Infliximab.
Adalimumab
Adalimumab may increase the immunosuppressive activities of Infliximab.
Anakinra
The risk or severity of adverse effects can be increased when Anakinra is combined with Infliximab.
Advertisement
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Infliximab.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Infliximab is combined with Anthrax immune globulin human.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Infliximab.
Advertisement
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Infliximab is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Infliximab is combined with Bacillus calmette-guerin substrain tice live antigen.
Belimumab
The risk or severity of adverse effects can be increased when Infliximab is combined with Belimumab.
Advertisement
Canakinumab
The risk or severity of infection and neutropenia can be increased when Infliximab is combined with Canakinumab.
Certolizumab Pegol
The risk or severity of infection can be increased when Infliximab is combined with Certolizumab pegol.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Infliximab.
Etanercept
Etanercept may increase the immunosuppressive activities of Infliximab.
Fingolimod
Infliximab may increase the immunosuppressive activities of Fingolimod.
Golimumab
Golimumab may increase the immunosuppressive activities of Infliximab.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Infliximab is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Infliximab is combined with Hepatitis B Vaccine (Recombinant).
Leflunomide
The risk or severity of adverse effects can be increased when Infliximab is combined with Leflunomide.
Natalizumab
The risk or severity of adverse effects can be increased when Infliximab is combined with Natalizumab.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Infliximab.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Infliximab.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Infliximab is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The risk or severity of adverse effects can be increased when Infliximab is combined with Rabies virus inactivated antigen, A.
Rilonacept
The risk or severity of adverse effects can be increased when Infliximab is combined with Rilonacept.
Rituximab
The risk or severity of adverse effects can be increased when Infliximab is combined with Rituximab.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Infliximab.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Infliximab is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Infliximab is combined with Rubella virus vaccine.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Infliximab is combined with Salmonella typhi ty21a live antigen.
Sarilumab
Sarilumab may increase the immunosuppressive activities of Infliximab.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Infliximab.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Infliximab.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Infliximab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tocilizumab
The risk or severity of adverse effects can be increased when Tocilizumab is combined with Infliximab.
Tofacitinib
The risk or severity of adverse effects can be increased when Infliximab is combined with Tofacitinib.
Trastuzumab
Trastuzumab may increase the neutropenic activities of Infliximab.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Infliximab is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Infliximab is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Ustekinumab
Ustekinumab may increase the immunosuppressive activities of Infliximab.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Infliximab is combined with Varicella Zoster Vaccine (Live/Attenuated).
Vedolizumab
The risk or severity of infection can be increased when Infliximab is combined with Vedolizumab.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Infliximab is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Infliximab is combined with Yellow Fever Vaccine.
